| Similar Articles |
|---|
 |
Pharmaceutical Executive
July 10, 2014
William Looney |
Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead.   |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Pharmaceutical Executive
June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
Pharmaceutical Executive
April 1, 2007
Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
Pharmaceutical Executive
April 10, 2014
Christini & Kaitin |
Regional Trends in Bioinnovation Investment Can the Cambridge model be duplicated? |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Pharmaceutical Executive
April 1, 2014
William Looney |
The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
The Motley Fool
August 23, 2004
Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
Pharmaceutical Executive
June 1, 2007
Michael Goodman |
A Very Specialty Moment Big Pharma is on a shopping spree for biologics and other specialty products. It has the money to buy them. But does it have the mojo to develop and market them successfully - or will the mid-size biopharmas make their big move? |
Pharmaceutical Executive
January 1, 2012
William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive
April 1, 2012
William Looney |
IP: Time for a Reset? Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive
August 1, 2011
William Looney |
Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation. |
Pharmaceutical Executive
May 1, 2012
William Looney |
Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever. |
Pharmaceutical Executive
September 1, 2008
Zhu Shen |
Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital. |
Pharmaceutical Executive
July 3, 2007
Walter Armstrong |
Take Me to Your Leader Turnover in the top 10 pharmas has new CEOs racing to reinvent the way their companies do business. Running a large pharmaceutical company has becoming immensely complex, and requires a broad set of management skills. Even then, a CEO may never see a beloved molecule approved for drughood. |
Fast Company
November 1, 2007
Tinker Ready |
Drug Flow and Deal Flow The news at this year's Biotech Investing confab will focus on Big Pharma companies, as they take a more active role in developing early-stage drugs. |
Pharmaceutical Executive
May 1, 2007
Waseem Noor |
Toolkit: How To Be a Better Partner Big pharmas and little biotechs have been getting hitched for years. Now it's time to add a little innovation to the relationship. Three new rules will keep the game exciting. |
Pharmaceutical Executive
January 1, 2009
Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
Pharmaceutical Executive
December 1, 2011
William Looney |
2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item. |
Pharmaceutical Executive
January 1, 2009
Walter Armstrong |
Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges. |
Pharmaceutical Executive
July 1, 2012 |
Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale? |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
Pharmaceutical Executive
October 1, 2008
Patrick Clinton |
Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there? |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
Chemistry World
July 25, 2008
Sarah Houlton |
Small is beautiful for GSK drug discovery New GlaxoSmithKline chief executive Andrew Witty is restructuring the firm's drug discovery, setting up small, highly focussed research teams that will have to bid for funding. |
Pharmaceutical Executive
April 1, 2007
Bill Trombetta |
Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes? |
The Motley Fool
February 22, 2005
Charly Travers |
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
The Motley Fool
February 17, 2011
Brian Orelli |
What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate. |
Bio-IT World
February 10, 2003
Malorye Branca |
The Art of the Deal Vertex Pharmaceuticals CEO Joshua Boger speaks about deal making and his company's success. |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
Pharmaceutical Executive
October 1, 2005
Mark J. Ahn |
It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights. |
BusinessWeek
March 7, 2005
Arlene Weintraub |
Where VCs Fear To Tread Angel investors are filling a critical gap by providing early backing for biotechs. |
Pharmaceutical Executive
June 1, 2012
Ben Comer |
Disruption in the C-Suite Clayton Christensen, author of "The Innovator's Dilemma," offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity. |
Pharmaceutical Executive
February 1, 2007
Ben Bonifant et al. |
Driven to License The competition for innovative biotech products is intense, giving rise to an unprecedented diversity of partnering strategies and an equally unprecedented convergence of small-molecule drugs and biologics in company portfolios. Licensings are shaping up as the year's big deal. |
Pharmaceutical Executive
August 1, 2011
Bill Drummy |
The Slow Dance Toward Obsolescence Does Big Pharma have the emotional connection and intellectual commitment to move with the pace of change? |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
